Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2022 Earnings Call Transcript

Reshma Rangwala: Yes. So let me talk about the TSS50 data. So we’ll have an opportunity to present additional TSS50 data at the next update, largely because patients filled out forms from a symptom perspective. Physicians also collected the same symptom data in their medical charts. So we can use these 2 platforms, i.e., the forms as well as the medical chart data to really provide a comprehensive overview of the TSS50 that has been achieved in the combination. So look forward to presenting that additional data in the first half of this year. In terms of the week 48 data, yes, absolutely. So we’ve got multiple patients that are staying on therapy. Some patients are coming in. They’ve been dosed for approximately a year. So being able to provide this durability data is going to be an opportunity again for us in the first half of this year.

In terms of the other competitor trials within the first-line space, by and large, I mean, look forward to seeing those data, but I don’t think that they’re necessarily influencing our decision about the design. As I mentioned previously, this is really a very traditional Phase III. We want to be able to demonstrate the benefit that can be achieved with the combination as compared to rux alone. So it is really going to be a very traditional Phase III of combination rux alone , focusing on that SVR and TSS50.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Richard Paulson for any closing remarks.

Richard Paulson: Thank you, operator, and thank you, everyone, for joining us on today’s call. And once again, a huge thank you to all of our teams and our people across the organization as each and every person at Karyopharm is working every day to say, how can we improve the lives for patients suffering from cancer. And we look forward to sharing an update with you here in the near future.

Operator: The conference has now concluded. Thank you for attending today’s presentation, and you may now disconnect.